CytoMed Therapeutics (GDTC) vs Intensity Therapeutics (INTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Intensity Therapeutics (INTS) has outperformed CytoMed Therapeutics (GDTC) over the past year, losing 48.4% versus a loss of 56.5%. Intensity Therapeutics is the larger company by market cap ($12.0 million vs $11.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GDTC | INTS |
|---|---|---|
| Share price | $0.9449 | $3.68 |
| Market cap | $11.28M | $12.01M |
| 1-day change | -3.56% | -3.16% |
| YTD return | -29.22% | -64.10% |
| 1-year return | -56.46% | -48.35% |
| EPS (TTM) | $-0.23 | $-3.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.68 | $43.50 |
| 52-week low | $0.68 | $3.21 |
| Distance from 52-week high | -74.32% | -91.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +340.26% | +425.27% |
| Average volume | 78.66K | 25.93K |
| Shares outstanding | 11.93M | 3.26M |
| Employees | 42 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Healthcare · Biotechnology · 42 employees
About Intensity Therapeutics
INTS stock →Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Healthcare · Biotechnology · 5 employees
GDTC vs INTS FAQ
Which is bigger, CytoMed Therapeutics or Intensity Therapeutics?
Intensity Therapeutics (INTS) is larger, with a market capitalization of $12.01M compared with $11.28M for CytoMed Therapeutics (GDTC).
Which stock has performed better over the past year, GDTC or INTS?
INTS returned -48.35% over the past 12 months, compared with -56.46% for GDTC (price return, excluding dividends). Past performance does not predict future results.
Are CytoMed Therapeutics and Intensity Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.